FLASH radiotherapy preserves T cells and increases immune infiltration in HPV-positive tumor models

FLASH RT preserved tumor-draining lymphocyte populations and increased intratumoral CD8+ infiltration compared with conventional dose-rate irradiation in HPV-positive mouse models.

KEY POINTS

  • This preclinical study from MD Anderson Cancer Center investigated whether ultrahigh-dose-rate FLASH radiotherapy could preserve lymphocytes while maintaining immunogenic signaling in HPV-positive tumors. Experiments used TC-1 and mEER murine cancer cell lines and syngeneic C57BL/6 mice bearing subcutaneous mEER tumors, comparing conventional dose-rate irradiation with FLASH delivery using a 9-MeV electron accelerator.
  • In vivo treatment delivered 27 Gy in three consecutive daily fractions of 9 Gy, with mean dose rates of approximately 270 Gy/s for FLASH versus 0.2 Gy/s for conventional RT. Tumors, peripheral blood and tumor-draining lymph nodes were collected two days after the final fraction, allowing assessment of early immunological changes rather than long-term tumor response or survival.
  • In HPV-positive TC-1 cells, FLASH increased expression of several immunogenic signaling markers, including calreticulin (CALR), HMGB1 and components of the cGAS–STING pathway, compared with conventional irradiation. At 9 Gy, HMGB1 expression was 4.17-fold versus 0.97-fold relative to sham, while STING expression was 2.2-fold versus 0.9-fold (both p<0.001). Responses were less consistent in mEER cells, and TC-1 clonogenic survival did not differ significantly between dose rates (p=0.87).
  • FLASH was associated with greater preservation of lymphocytes in tumor-draining lymph nodes. Mean absolute CD8+ T-cell counts were 1.7 × 10⁴ versus 0.8 × 10⁴ with conventional RT (p<0.001), while CD4+ T-cell counts were 2.3 × 10⁴ versus 1.2 × 10⁴ (p<0.001). Lymphocyte numbers after FLASH approached those observed in nonirradiated control mice.
  • The lymphocyte-sparing association extended to functionally relevant T-cell subsets. In tumor-draining nodes, effector-like CD8+ T cells increased from 0.5 × 10³ after conventional RT to 2.2 × 10³ after FLASH (p<0.001), while corresponding effector-like CD4+ T cells increased from 3.3 × 10³ to 11 × 10³ (p<0.01). These differences suggest greater preservation of antigen-experienced lymphocytes during the early post-irradiation period.
  • Multiplex immunofluorescence showed substantially greater intratumoral immune-cell infiltration after FLASH. CD8+ T-cell density was 57.4 versus 16.7 cells/mm² after conventional RT (p<0.05), representing approximately 3.4-fold higher infiltration. However, the proportion of PD-1-positive CD8+ cells increased from 6.2% to 31.0%, and PD-L1-positive tumor-associated macrophages increased from 0.54% to 11.3% (both p<0.05), indicating simultaneous preservation of potentially immunosuppressive checkpoint signaling.
  • The findings therefore suggest a complex immune response rather than uniformly enhanced antitumor immunity. Greater lymphocyte preservation and immunogenic-marker expression coexist with increased PD-1/PD-L1 signaling, raising a hypothesis for combining FLASH with checkpoint inhibitors. However, checkpoint blockade was not tested, and the study did not measure long-term tumor control, survival or clinical toxicity; immune profiling was largely limited to a single early time point in subcutaneous murine tumors.

CLINICAL TAKEAWAY

FLASH irradiation may influence antitumor immunity beyond conventional normal-tissue sparing, preserving lymphocyte populations while increasing immune infiltration and immunogenic signaling in HPV-positive preclinical models. The simultaneous increase in PD-1/PD-L1 expression suggests a possible rationale for combination strategies, but these observations remain mechanistic and do not establish improved tumor control, immunotherapy synergy or clinical benefit.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction